Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Mair MJ, Ilhan-Mutlu A, Pajenda S, Kiesel B, Wöhrer A, Widhalm G, Dieckmann K, Marosi C, Wagner L, Preusser M, Berghoff AS.
Mair MJ, et al. Among authors: widhalm g.
Cancer Immunol Immunother. 2021 Dec;70(12):3643-3650. doi: 10.1007/s00262-021-02951-2. Epub 2021 May 6.
Cancer Immunol Immunother. 2021.
PMID: 33956203
Free PMC article.